ArticleCytotechnology2025
LncRNA PSMA-AS1 affects glioma cell metastasis through mediating pyroptosis via miR-140-3p/SRSF10 axis.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is a malignant primary tumor of the brain. In recent years, numerous LncRNAs (Long non-coding RNA) have been demonstrated to be potential targets for glioma, and induction of pyroptosis is one of the important directions to inhibit the malignant process of cancer. The role of LncRNA PSMA-AS1, a novel lncRNA, on glioma remain unclear. The aim of this study was to investigate the effects and mechanisms of LncRNA PSMA-AS1 on glioma. PSMA1-AS1 and its potential targets were analyzed using bioinformatics tools and validated using a dual luciferase reporter gene system. Glioma cells were cultured to detect the expression levels of PSMA1-AS1 and its targets. The levels of PSMA1-AS1 and its targets were regulated by transfection and their effects on the viability and metastatic ability of glioma cells as well as on the level of pyroptosis were examined. PSMA1-AS1 expression was elevated in glioma, where miR-140-3p was a downstream target, and was decreased in glioma cells. Inhibition of PSMA1-AS1 promoted pyroptosis and inhibited glioma cell viability and metastatic ability. Overexpression of miR-140-3p had the same effect as inhibition of PSMA1-AS1, whereas inhibition of miR-140-3p reversed the effect of inhibition of PSMA1-AS1 on glioma cells. In addition, SRSF10 is a downstream binding target of miR-140-3p, and inhibition of SRSF10 also promoted pyroptosis and inhibited glioma cells proliferation and metastasis. In conclusion, our results confirmed that PSMA1-AS1 affects glioma cell proliferation and metastasis by regulating pyroptosis through miR-140-3p/SRSF10 axis, suggesting that LncRNA PSMA1-AS1 may be a potential target for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.